Alkermes Increases Offer for Avadel Acquisition

Alkermes ( (ALKS) ) has shared an announcement.

On November 18, 2025, Alkermes plc and Avadel Pharmaceuticals plc amended their transaction agreement, increasing the cash consideration for the acquisition of Avadel to $21.00 per share, while maintaining the contingent value right terms. This move followed Avadel’s receipt of a superior proposal from H. Lundbeck A/S, which was later deemed inferior to Alkermes’ revised offer. Additionally, Alkermes entered into an amended bridge loan agreement to finance the acquisition, ensuring compliance with Irish Takeover Code requirements. The acquisition is expected to close in the first quarter of 2026.

The most recent analyst rating on (ALKS) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.

Spark’s Take on ALKS Stock

According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.

Alkermes’ strong financial performance and positive earnings call are the primary drivers of its stock score. The company’s strategic acquisition and raised guidance reflect confidence in future growth. Technical indicators support a positive trend, while valuation remains reasonable. Increased expenses are a minor concern but are outweighed by the company’s growth prospects.

To see Spark’s full report on ALKS stock, click here.

More about Alkermes

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio that includes treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company is headquartered in Ireland and operates a corporate office and research center in Massachusetts, as well as a manufacturing facility in Ohio.

Average Trading Volume: 2,398,186

Technical Sentiment Signal: Buy

Current Market Cap: $4.84B

Find detailed analytics on ALKS stock on TipRanks’ Stock Analysis page.